EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products

Ye Xiong, Robyn Konicki, Jeanne Fourie Zirkelbach, Youwei Bi, Olanrewaju Okusanya, Stacy Shord, Nam Atiqur Rahman, Brian Booth, Yangbing Li, Jiang Liu, Hao Zhu iD

The Oncologist · 08.05.2026 · 31 (6)

DOI: 10.1093/oncolo/oyag154 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 04.05.2026. Verfasst von Ye Xiong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, Food and Drug…. Hauptthemen laut MEDLINE: Drug Development, Antineoplastic Agents, Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Applying model-based approaches to leverage clinical and non-clinical data can support the identification of optimized dosage(s) for oncology products and allow for a better benefit-risk balance. In oncology, conventional dose-finding studies may lead to the selection of a poorly optimized dosage into subsequent studies, including those designed to demonstrate safety and efficacy in support of a marketing application. As a result, the clinical data obtained may be insufficient to optimize the benefit-risk profile of the drug without postmarketing studies. Model-informed drug development (MIDD), which includes modeling and simulation (eg, quantitative system pharmacology, empirical or mechanistic pharmacokinetic/pharmacodynamic models), and integrative exposure-response analysis, can significantly enhance dosage selection and optimization. This review provides an update on the recent utilization and unique challenges of MIDD for dosage optimization in oncology drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentAntineoplastic AgentsNeoplasmsHumansDose-Response Relationship, Drug

Stichwörter der Autor:innen

MIDDProject Optimusdosage optimization

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States.
  • Division of Cancer Pharmacology II, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States.
  • Division of Cancer Pharmacology I, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States.

ORCID-Profile: Hao Zhu

Zitieren

APA

Xiong, Y., Konicki, R., Zirkelbach, J. F., Bi, Y., Okusanya, O., Shord, S., Rahman, N. A., Booth, B., Li, Y., Liu, J., & Zhu, H. (2026). Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag154

Vancouver

Xiong Y, Konicki R, Zirkelbach JF, Bi Y, Okusanya O, Shord S, et al. Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag154

BibTeX
@article{Xiong2026,
  author = {Xiong, Ye and Konicki, Robyn and Zirkelbach, Jeanne Fourie and Bi, Youwei and Okusanya, Olanrewaju and Shord, Stacy and Rahman, Nam Atiqur and Booth, Brian and Li, Yangbing and Liu, Jiang and Zhu, Hao},
  title = {Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {6},
  doi = {10.1093/oncolo/oyag154}
}
Kostenlos starten →